Patients with ovarian serous cancer and an overexpression of the HER4 protein are less likely to respond to chemotherapy and have a lower rate of survival, research shows.
Patients with ovarian serous cancer and an overexpression of the HER4 protein are less likely to respond to chemotherapy and have a lower rate of survival, research shows.